Many of the treatments available for hepatitis C include sofosbuvir. Unfortunately sofosbuvir has not been cleared for use in patients with eGFR under 30 ml/min/1.73m2 leaving these group of patients with few options. Nevertheless, there are many reports in which patients with renal failure have been treated with sofosbuvir-containing regiments without any important adverse events

We enrolled subjects with severely impaired renal function infected with hepatitis C from 13 centers. Severe renal failure was defined as eGFR under 30 ml/min/1.73m2 or hemodialysis

A total of 96 patients were enrolled in the study. Mean age of subjects was 50.0 years.

The combination of sofosbuvir and daclatasvir is an extremely effective and safe treatment for patients infected with all genotypes of hepatitis C who have severely impaired renal function, including hemodialysis patients.